Filgrastim biosimilar - Lupin

Drug Profile

Filgrastim biosimilar - Lupin

Alternative Names: Filgrastim - Lupin; Lupifil

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lupin
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 19 May 2016 Launched for Neutropenia (Adjunctive treatment, In adults) in India before May 2016 (SC) (Lupin website, July 2016)
  • 23 Apr 2014 Phase-III clinical trials for Neutropenia (adjunct to chemotherapy in patients with non-myeloid malignancies) in India (SC)
  • 08 Aug 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top